Anti-infection 1.1 New Drug PL-5 is approved to be in Clinical Trial


On April 15th, CFDA announced on internet that anti-infection 1.1 new drug PL-5 of Jiangsu ProteLight Pharma was approved to be in clinical trial, which is the first antimicrobial peptide innovative drug in clinical trial in China. With characters of low toxicity, high efficiency and anti-drug resistant bacteria, PL-5 has a significant advantage of disinfecting “the super bacteria”, which is resistant to traditional antibiotics. Antimicrobial peptide PL-5 being in clinical trial can relieve the suffering of patients with skin infection.